ATE290548T1 - Expressionsblockierung von virulenten faktoren in s. aureus - Google Patents

Expressionsblockierung von virulenten faktoren in s. aureus

Info

Publication number
ATE290548T1
ATE290548T1 AT97927727T AT97927727T ATE290548T1 AT E290548 T1 ATE290548 T1 AT E290548T1 AT 97927727 T AT97927727 T AT 97927727T AT 97927727 T AT97927727 T AT 97927727T AT E290548 T1 ATE290548 T1 AT E290548T1
Authority
AT
Austria
Prior art keywords
aureus
expression blocking
peptides
virulent factors
expression
Prior art date
Application number
AT97927727T
Other languages
English (en)
Inventor
Richard P Novick
Guangyong Ji
Ronald Beavis
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Application granted granted Critical
Publication of ATE290548T1 publication Critical patent/ATE290548T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Control Of Combustion (AREA)
  • Air Conditioning Control Device (AREA)
  • Heat Treatment Of Steel (AREA)
  • Electrotherapy Devices (AREA)
AT97927727T 1996-05-22 1997-05-22 Expressionsblockierung von virulenten faktoren in s. aureus ATE290548T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65122696A 1996-05-22 1996-05-22
PCT/US1997/008791 WO1997044349A1 (en) 1996-05-22 1997-05-22 BLOCKING EXPRESSION OF VIRULENCE FACTORS IN $i(S. AUREUS)

Publications (1)

Publication Number Publication Date
ATE290548T1 true ATE290548T1 (de) 2005-03-15

Family

ID=24612055

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97927727T ATE290548T1 (de) 1996-05-22 1997-05-22 Expressionsblockierung von virulenten faktoren in s. aureus

Country Status (8)

Country Link
EP (1) EP0932613B1 (de)
JP (1) JP2000511537A (de)
AT (1) ATE290548T1 (de)
AU (1) AU735283B2 (de)
CA (1) CA2256465A1 (de)
DE (1) DE69732709T2 (de)
PT (1) PT932613E (de)
WO (1) WO1997044349A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9724859D0 (en) * 1997-11-26 1998-01-21 Univ Nottingham Compounds and their use as antibacterial agents
US6291431B1 (en) 1997-12-19 2001-09-18 Panorama Research Methods and compositions for the treatment and prevention of Staphylococcal infections
US7534857B2 (en) 1997-12-19 2009-05-19 Centegen, Inc. Methods and compositions for the treatment and prevention of staphylococcal infections
US7323179B2 (en) 1997-12-19 2008-01-29 Naomi Balaban Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
US6337385B1 (en) 1998-06-24 2002-01-08 The Rockefeller University Staphylococcus peptides for bacterial interference
EP1090034A2 (de) * 1998-06-24 2001-04-11 The Rockefeller University Neue peptide aus staphylococcus zur bakteriellen hemmung
US6747129B1 (en) 1998-09-15 2004-06-08 The Regents Of The University Of California Target of RNAIII activating protein(TRAP)
EP1862549A3 (de) 1998-09-15 2008-02-13 Naomi Balaban Target eines RNAIII-aktivierenden Proteins (TRAP)
EP1188831B1 (de) * 1998-09-15 2007-12-05 Naomi Balaban Ziel des RNAIII activierenden Proteines (TRAP)
AU2001238115A1 (en) * 2000-02-10 2001-08-20 Intermune, Inc. Novel amino acid and peptide inhibitors of staphylococcus virulence
JP4070464B2 (ja) * 2000-02-23 2008-04-02 日本植生株式会社 植物生長促進剤及び植物生長促進方法
US7824691B2 (en) 2005-04-04 2010-11-02 Centegen, Inc. Use of RIP in treating staphylococcus aureus infections
AU2008317331B2 (en) * 2007-10-25 2013-08-29 The Scripps Research Institute Antibody-mediated disruption of quorum sensing in bacteria
ES2682595T3 (es) * 2015-03-23 2018-09-21 Eberhard Karls Universität Tübingen Nuevo compuesto antiinfeccioso
WO2017136400A1 (en) * 2016-02-02 2017-08-10 Stc. Unm Vlp-based vaccines for targeting staphylococcus aureus secreted virulence factors
US20210177917A1 (en) * 2017-08-31 2021-06-17 The Regents Of The University Of California Molecular bacteriotherapy to control skin enzymatic activity
KR102199062B1 (ko) * 2019-09-27 2021-01-06 코스맥스 주식회사 스타필로코커스 자일로서스 st-10 균주 및 그의 피부 상태 개선 용도
KR102195998B1 (ko) * 2019-09-27 2020-12-29 코스맥스 주식회사 스타필로코커스 시뮬란스 st-9 균주 및 그의 피부 상태 개선 용도
KR102286075B1 (ko) * 2019-09-27 2021-08-05 코스맥스 주식회사 스타필로코커스 렌투스 st-2 균주 및 그의 피부 상태 개선 용도
CN118931767B (zh) * 2024-07-24 2025-03-25 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) 一株纹带棒状杆菌nmgcs43及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3825995A (en) * 1994-10-04 1996-04-26 New York University Blocking expression of virulence factors in s. aureus

Also Published As

Publication number Publication date
AU735283B2 (en) 2001-07-05
CA2256465A1 (en) 1997-11-27
EP0932613A1 (de) 1999-08-04
WO1997044349A1 (en) 1997-11-27
DE69732709T2 (de) 2006-06-29
AU3211797A (en) 1997-12-09
EP0932613B1 (de) 2005-03-09
JP2000511537A (ja) 2000-09-05
PT932613E (pt) 2005-06-30
DE69732709D1 (de) 2005-04-14
EP0932613A4 (de) 2002-01-09

Similar Documents

Publication Publication Date Title
DE69732709D1 (de) Expressionsblockierung von virulenten faktoren in s. aureus
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
EP0766674A4 (de) Neue hiv-protease-inhibitoren
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
WO2003099110A3 (en) Herbs and herbal combinations useful for the treatment of microbial infections
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
TR199903053T2 (xx) Benzimidazol t�revleri.
PL328858A1 (en) Immunogenous peptides
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
DE60041753D1 (de) Arzneimittel zur behandlung von c. pneumoniae infektionen
ATE335499T1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
PT934065E (pt) Compostos farmaceuticos
EP0734387A4 (de) Hiv-proteaseinhibitoren
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
WO2000063386A3 (en) Prevention, diagnosis and treatment of lyme disease
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
ATE303816T1 (de) Neue therapeutische verwendung eines eine virale ansteckung modulierendes protein zur verhinderung von abstossung von fremdtransplantaten
BR0111785A (pt) Composições e métodos para tratamento de candidìase
EA200101171A1 (ru) Способ лечения инфекций, вызванных streptococcus pneumoniae
ATE313628T1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
BG101145A (bg) Използване на /s/-аденозил-l-метионин /саме/ i неговите физиологично съвместими соли за лечение нареперфузионно увреждане, причинено от временна фокална исхемиа
ATE255594T1 (de) Hepatitis b inhibitoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0932613

Country of ref document: EP

REN Ceased due to non-payment of the annual fee